Meet Eris, The COVID Variant Behind A Summer Resurgence In Cases: 3 Drugmakers Prep Fall Booster Shots
Portfolio Pulse from AJ Fabino
The COVID-19 variant EG.5 is causing a resurgence in cases, accounting for an estimated 17.3% of all cases in the U.S. In response, Pfizer Inc (PFE), BioNTech SE (BNTX), Moderna Inc (MRNA), and Novavax Inc (NVAX) are preparing to release updated vaccines by the end of September, pending FDA and CDC approval. The new vaccines will primarily target the XBB variants, descendants of the original Omicron strain.
August 11, 2023 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioNTech is preparing to release an updated vaccine targeting the XBB variants of COVID-19.
The development of a new vaccine could potentially increase BioNTech's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Moderna is preparing to release an updated vaccine targeting the XBB variants of COVID-19.
The development of a new vaccine could potentially increase Moderna's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Novavax is preparing to release an updated vaccine targeting the XBB variants of COVID-19.
The development of a new vaccine could potentially increase Novavax's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer is preparing to release an updated vaccine targeting the XBB variants of COVID-19.
The development of a new vaccine could potentially increase Pfizer's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100